Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for potentially curative treatment of HBV infections.
Our lead therapeutic candidate, ATI-2173, is a first-in-class Active Site Polymerase Inhibitor Nucleotide (ASPIN) that is in clinical development as the backbone of an oral, once-daily potential curative therapy for Hepatitis B Virus. To date, we have completed extensive pre-clinical work, as well as Phase 1 studies in both healthy volunteers and HBV-infected individuals. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
Total Funding: $125.4 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Antios Therapeutics